Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
OpenAI Restricts Astra AI Over Cyberattack Risks 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SAN DIEGO, March 06, 2018 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 30th Annual ROTH Conference at 1:00 pm PT (4:00 pm ET) on Tuesday, March 13, 2018, at the Ritz Carlton in Dana Point, CA.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact:
Patricia Bitar
Chief Financial Officer
(858) 550‐0780 ext. 223
[email protected]
Investor Contact:
Andrew McDonald
LifeSci Advisors LLC
646-597-6987
[email protected]
